[Uterine cervix cancer. Clinical stage III. Combined radiotherapy and chemotherapy treatment].
55 patients with stage III carcinoma of the uterine cervix were entered into a prospective randomized study to evaluate the possible radiation-potentiating properties of bleomycin. Group A received classical radiation treatment with telecobalt-therapy 50 Gy/25 fractions plus 32 Gy/4 fractions (Cathetron). The other two groups received 15 mg of bleomycin by continue infusion two time of week during 5 week, groups B before, and group C after, irradiation. The morbidity was minimal. The initial response was complete in 49 cases and partial in 6 cases. At 2 years there were 26 recurrences, 22 (88.8%), locoregional recurrences and 4 distant metastasis, 3 in the group of bleomycin treatment. The probability of actuarial survival was 62.1%, 30.1% and 35.6% respectively to groups A, B and C. Addition of bleomycin to radiotherapy failed to increase the recurrence-free survival.
Ayala Hernández
J R
JR
Departamento de Radioterapia, Hospital de Oncología, CMN, IMSS.
de la Huerta Sánchez
R
R
Morales Canfield
F
F
Fernández Orozco
A
A
D000206:Actuarial Analysis; D001761:Bleomycin / Q000627:therapeutic use*; D001918:Brachytherapy; D017024:Chemotherapy, Adjuvant; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D010865:Pilot Projects; D011867:Radioisotope Teletherapy; D012074:Remission Induction; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*
D003037:Cobalt Radioisotopes; D001761:Bleomycin
Cáncer cervicouterino. Etapa clínica III. Tratamiento combinado de radioterapia y quimioterapia.